European Medicines Agency validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as adjuvant treatment for resected esophageal or gastroesophageal junction cancer following chemoradiotherapy
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients
